CGD

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Retrieved on: 
onsdag, maj 8, 2024
FDA, Process, Chronic granulomatous disease, Mutation, Mouse, Cell, CGD, Food, Hematology, Life, U.S. FDA, IND, Neutrophil, NADPH, Patient, Society, Immunology, Stem cell, Fungus, Health, NCF1, Pharmaceutical industry

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be presented today at an oral presentation during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore. Prime Medicine recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for PM359 for the treatment of CGD.

Key Points: 
  • The data will be presented today at an oral presentation during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore.
  • Prime Medicine recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for PM359 for the treatment of CGD.
  • Prime Medicine is advancing an ex vivo Prime Editing program, PM359, that aims to correct the predominant mutation in NCF1 in CGD patient CD34+ hematopoietic stem cells (HSCs) and restore NADPH oxidase function.
  • In today’s presentation at ASGCT, Prime Medicine highlighted data from a series of in vivo non-clinical studies using human CGD patient CD34+ HSCs.

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Retrieved on: 
tisdag, april 23, 2024
Chronic granulomatous disease, CGD, Cell, Conference, Society, Prime editing, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting (Baltimore, May 7-11, 2024); and TIDES USA Oligonucleotide & Peptide Therapeutics Conference (Boston, May 14-17, 2024).

Key Points: 
  • “In the short time since Prime Editing was first discovered, we have made incredible strides advancing this technology, developing and optimizing Prime Editors for programs across our core areas of focus, and creating new delivery systems that we believe will permit our Prime Editors to safely and effectively access target tissue,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
  • In addition to our presentations, we congratulate our Co-Founder, David Liu, on receiving the ASGCT Outstanding Achievement Award, highlighting his work in the gene editing field, including his contributions to the discovery and advancement of Prime Editing.
  • We look forward to coming together with the scientific research community and highlighting our leading position in the field of next-generation gene editing.”
    Details of the presentations are as follows.
  • Presentation Name: Advancing LNP Screening to Incorporate Automated, High-Throughput Readouts

Osaka Gas, Sumitomo, and JOIN to Invest in Expanding City Gas Distribution Business in India

Retrieved on: 
måndag, april 15, 2024
Oil, Gas, Energy, Osaka Gas, OGS, CGD, Air pollution, Natural gas, Marketing, CNG, AG, Sumitomo Corporation, PTE, Transport, Carbon, JOIN, Multimedia, Government, Knowledge

Osaka Gas Co., Ltd. (Osaka Gas) announced on April 8 its subsidiary OSAKA GAS SINGAPORE PTE.

Key Points: 
  • Osaka Gas Co., Ltd. (Osaka Gas) announced on April 8 its subsidiary OSAKA GAS SINGAPORE PTE.
  • Ltd. (AG&P LNG Marketing), aiming to boost AG&P LNG Marketing’s city gas distribution (CGD) business in India.
  • This marks OGS’ second major investment in the CGD business in India, following the first one in 2021.
  • City gas suppliers are selected in a bidding process for each GA and given exclusive gas sales and infrastructure rights (exclusive business rights) for an agreed period.

Business as usual: bank climate commitments, lending, and engagement

Retrieved on: 
tisdag, april 2, 2024
Smoke, Carbon, Pillar, Worldwide, BPER, Employment, Disclosure, Economic methodology, LEI, Research Papers in Economics, CGD, Ibercaja Banco, Fossil, Mediobanca, Policy, UNEP, Crédit Mutuel, BBVA, Columbia Business School, Pari, Corporate finance, NBER, Principle, Agriculture, Société Générale, Insurance, Allied Irish Banks, Medical classification, Aluminium, Becker, Feedback, Central bank, Triodos Bank, Target, Prosocial behavior, Journal of Financial Economics, European Parliament, MIT, R2, Website, Behavior, Poisson, Human, UN, Climate, Crédit Agricole, United Nations, Transport, Coal mining, Syndicated loan, Investment, ABN AMRO, Politics, BSI, OLS, PDF, ECB, Unemployment, Econometrics, Ambition, Clutch (eggs), IEA, Social science, Engagement, JEL, Climate change, Risk management, Yb, Bias, Abanca, Research, Classification, UniCredit, A.5, NZIA, Divestment, Literature, IPCC, European Central Bank, AA, Geography, Natural gas, Green lending, Metal, The Borrowers, Elasticity, Stanford Social Innovation Review, Steven M. Greer, BMPS, Finance, Risk, Single, CaixaBank, PPML, BNP Paribas, European, Money, NLB Group, La Banque postale, Corporate welfare, Paris Agreement, A.2, ROW, OECD, Fraud, Coal, Frustration, Iron, Commerzbank, Bank of Åland, COP, Comparison, Overalls, All, Temperature, Banca Ifis, Conference, Pressure, Steel, International Energy Agency, United, Alpha Bank, Interest, SSRN, Justice, AAA, Deutsche Bank, Crawford, Science Based Targets initiative, GFANZ, Quarterly Journal, Rabobank, Hirschman, Effect, Carbon Disclosure Project, ESG, MSCI, Support, NZBA, Sierra Club, Map, Taxonomy, Q50, Banco Sabadell, Financial Times, Banco BPM, BPCE, Reproduction, Erste Group, Data, G21, Interval (mathematics), Cardboard
Key Points: 

    Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

    Retrieved on: 
    fredag, mars 1, 2024
    Sequence, Composition, Liver, RHO, Immunotherapy, Investment, FDA, Research and development, HSC, Food, CGD, Patent, SCIP, Lung, Ataxia, Cystic Fibrosis Foundation, Hematology, Administration, Patient, Target, IND, AAV, CTA, Pharmaceutical industry

    CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.

    Key Points: 
    • “In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients.
    • This funding will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
    • Gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
    • In January 2024, Prime Medicine announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer.

    Cambridge GaN Devices Moves to Support Industrial Applications With Higher Power Reference Designs and Demos

    Retrieved on: 
    tisdag, februari 27, 2024
    Consumer Electronics, Technology, Manufacturing, Semiconductor, Other Manufacturing, Green Technology, Software, Artificial Intelligence, Environment, Hardware, Sustainability, AGD, Silicon, APEC, Partnership, CGD, Electronics, Exposition, Conference, Gallium nitride, Artificial intelligence, Analog Devices, Electric motor

    Cambridge GaN Devices (CGD) , the fabless, clean-tech semiconductor company that develops energy-efficient GaN-based power devices that make greener electronics possible, is addressing higher power industrial applications with its ICeGaN™ technology which has already proved itself rugged, reliable and easy-to-use in high volume consumer devices.

    Key Points: 
    • Cambridge GaN Devices (CGD) , the fabless, clean-tech semiconductor company that develops energy-efficient GaN-based power devices that make greener electronics possible, is addressing higher power industrial applications with its ICeGaN™ technology which has already proved itself rugged, reliable and easy-to-use in high volume consumer devices.
    • At the APEC 2024, IEEE Applied Power Electronics Conference and Exposition, the company is introducing new reference designs and showing demos which address the broad and diverse industrial market.
    • Andrea Bricconi | Chief Commercial Officer, CGD
      “We are acutely aware of the increasing power requirements of industrial applications, and the need for high efficiency.
    • This is the first time the company has used a 100% GaN power transistor design for both the power stage and the amplifier.

    Cambridge GaN Devices Addresses Challenges of Datacentres and More at APEC 2024

    Retrieved on: 
    tisdag, februari 13, 2024
    Hardware, Chemicals, Plastics, Semiconductor, Data Management, Green Technology, Energy, Sustainability, Manufacturing, Technology, Professional Services, Environment, Artificial Intelligence, Other Manufacturing, Other Energy, Data Analytics, Engineering, Great Vowel Shift, MOSFET, APEC, Innovation system, CGD, Electronics, Exposition, Business development, Conference, Immunity, Gallium nitride, Artificial intelligence, Management

    Cambridge GaN Devices (CGD) , the fabless, clean-tech semiconductor company that develops energy-efficient GaN-based power devices that make greener electronics possible, will be present at the upcoming APEC 2024, IEEE Applied Power Electronics Conference and Exposition.

    Key Points: 
    • Cambridge GaN Devices (CGD) , the fabless, clean-tech semiconductor company that develops energy-efficient GaN-based power devices that make greener electronics possible, will be present at the upcoming APEC 2024, IEEE Applied Power Electronics Conference and Exposition.
    • Giorgia Longobardi | Chief Executive Officer, CGD
      “With datacentres now demanding 100kW per rack and predicting even more in the very near future, power system designers are looking to employ GaN devices in new architectures.
    • Thursday 29th February, 09.45-10.10 – ‘Monolithic integration addresses the design challenges of GaN Power devices’, with Di Chen, Director of Business Development & Technical Marketing, CGD.
    • CGD has delivered industry’s most easy-to-use GaN technology – ICeGaN – and we are keen to share our ideas with the audience at APEC.”

    Tec Inc. Engineering & Design Announces Leadership Transition in Columbus Office with a Continued Commitment to Values

    Retrieved on: 
    fredag, januari 19, 2024
    Engineering, Heart, Quality assurance, Mechanical, Environment, Quality control, CPSM, AP, LEED, Technical, CGD, Mechanical engineering, Management

    COLUMBUS, Ohio, Jan. 19, 2024 /PRNewswire/ -- Tec Inc. Engineering & Design, a leading firm in the engineering and design industry, is pleased to announce key leadership changes in its Columbus office, effective January 1st, 2024.

    Key Points: 
    • COLUMBUS, Ohio, Jan. 19, 2024 /PRNewswire/ -- Tec Inc. Engineering & Design, a leading firm in the engineering and design industry, is pleased to announce key leadership changes in its Columbus office, effective January 1st, 2024.
    • Mr. Jon Alexander, PE, CGD, a seasoned leader known for his commitment to our core values, will assume the role of Managing Director.
    • In keeping with the "Commitment to Quality" philosophy at Tec Inc., Mr. Todd Miller, PE, LEED AP BD+C, will continue to serve as the Director of Mechanical Engineering in the Columbus office.
    • Todd Miller's continued leadership in Mechanical Engineering is a testament to our commitment to our talented and dedicated team," stated Adam Kilbourne.

    5th Anniversary丨Red Dot Design Museum Xiamen Grand Reopening

    Retrieved on: 
    tisdag, december 5, 2023
    Moonlight, Good Design, Media Group, Red Dot, Creativity, Xiamen Gaoqi International Airport, Collection, Medium (website), Commerce, Multimedia, Xiamen Media Group, Red, GOOD, Science, Humanities, Exhibition, CGD, Museum, Convention center, Good, Environment, Life, 3D printing, Entertainment, Interior design, Telescopic sight, Film industry, Nightclub

    XIAMEN, China, Dec. 5, 2023 /PRNewswire/ -- On the morning of the 28th, the opening ceremony "Accompanied by Good Design", concluded successfully in Jimei District, Xiamen.

    Key Points: 
    • In 2021, the temporary Red Dot Design Museum Xiamen was moved to Xiamen Fliport Convention and Exhibition Center.
    • Over the years, Red Dot Design Museum Xiamen has introduced more than 30 international professional exhibitions, attracted nearly 400,000 visitors, completed more than 500 professional events, gathered 600 global brand products, and provided training courses for more than 7,000 people...
      Red Dot Design Museum Xiamen presents the top level of design in various fields and the innovation of designers and design teams at multiple levels through high-quality international design exhibitions, forward-looking design trends and exploration discussions, and public education projects with advanced concepts.
    • Red Dot Design Museum Xiamen is committed to becoming a global design business watchtower, stimulating the creativity of local designers, and bringing good design closer to life.
    • On the afternoon of 28th, a large number of guests gathered at the event site of "Live Design Talk: ACCOMPANIED BY GOOD DESIGN", the 5th Anniversary Design Salon of Red Dot Design Museum Xiamen.

    Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

    Retrieved on: 
    fredag, november 3, 2023
    Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

    Key Points: 
    • 11,795,452 --
      CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
    • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
    • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
    • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.